Skip to main content
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices
Back to the NewsWire

Bioengineer

Published November 20, 2026 · Updated November 21, 2026

Psilocybin and Ketamine Improve Decision Accuracy in Mice by Reducing Repetitive Habits

Read the full story at Bioengineer

Their work addresses a critical gap in neurobiology, as the mechanisms through which psychedelics alter brain circuits to produce therapeutic and mind.

Surfaced by this Google Alert

  • Ketamine